Herein, of 398 PLK1‐mutated pan‐cancer tissue samples [including lung cancer, colorectal cancer (CRC), breast cancer, hepatobiliary cancer, genitourinary cancer, uterine cancer, etc.], we enrolled 126 patients with lung cancer (the LC cohort) and 160 patients with CRC (the CRC cohort) to profile the genomic landscape of PLK1 and concomitant mutations under natural selection within lung cancer and CRC, detailed in Table S1 and Table S2, respectively (Figure 1A). This evidence concerns the gene PLK1 and urogenital neoplasm.